{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-038366","form_type":"8-K","ticker":"VYCO","cik":"0001424768","company_name":"VYCOR MEDICAL INC","filed_at":"2026-08-14T20:13:30+00:00","discovered_at":"2026-08-14T20:20:44.190484+00:00","generated_at":"2026-08-14T20:20:52.072985+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vycor Medical Q2 revenue down 16% to $418K; operating profit falls to $6.9K","bullets":["Q2 2026 revenue $418,264, down 16% YoY; Vycor Medical division down 17% to $401,224 on international weakness.","Q2 operating profit $6,851 vs $51,146 in 2025; non-GAAP operating profit $22,952 vs $85,712.","Six-month revenue $876,804, down 6%; operating profit $52,659 vs $38,340 in 2025.","NovaVision in development: Q2 revenue $17,040, up 17% YoY; six-month $35,139, up 8%.","Three new peer-reviewed VBAS studies published in 2026; total now 53 peer-reviewed papers."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-038366","json":"https://secwatch.observer/filing/0001493152-26-038366.json","markdown":"https://secwatch.observer/filing/0001493152-26-038366.md","text":"https://secwatch.observer/filing/0001493152-26-038366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1424768/000149315226038366/0001493152-26-038366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1424768/000149315226038366/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:20:52.072985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}